PolyTherics Announces a Research Collaboration with Spirogen to Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

04-Apr-2012 - United Kingdom

PolyTherics Limited announced that it has formed a research collaboration with Spirogen Limited to develop antibody-drug conjugates (ADCs) that combine PolyTherics’ proprietary site-specific conjugation chemistry with Spirogen’s highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.    

Under the collaboration, the two companies will produce the ADCs using PolyTherics’ proprietary TheraPEG™ linker technology to site-specifically conjugate Spirogen’s potent pyrrolobenzodiazepines (“PBDs”) cytotoxic agents – known as warheads - to antibodies and antibody fragments. The companies will then test the potency of the resulting ADCs in preclinical models of cancer.  PolyTherics and Spirogen will jointly seek partners to develop the most promising ADC candidates that arise from the collaboration.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances